AR100010A1 - EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 - Google Patents

EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123

Info

Publication number
AR100010A1
AR100010A1 ARP140100533A ARP140100533A AR100010A1 AR 100010 A1 AR100010 A1 AR 100010A1 AR P140100533 A ARP140100533 A AR P140100533A AR P140100533 A ARP140100533 A AR P140100533A AR 100010 A1 AR100010 A1 AR 100010A1
Authority
AR
Argentina
Prior art keywords
chemeric
antigen
human leukemia
car
leukemia
Prior art date
Application number
ARP140100533A
Other languages
Spanish (es)
Inventor
H June Carl
Gill Saar
D Kalos Michael
Loew Andreas
Brogdon Jennifer
Scholler John
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag
Publication of AR100010A1 publication Critical patent/AR100010A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones y métodos para el tratamiento de la leucemia, por ejemplo, la leucemia mieloide aguda (LMA) y leucemia linfoide aguda de células B (B-LLA). También se refiere a al menos un receptor de antígeno quimérico (CAR) específico a CD123, vectores que comprenden el mismo, y células T recombinantes que comprenden el CAR-CD123. También incluye métodos de administración de una célula T modificada genéticamente que expresa un CAR que comprende un dominio de unión a CD123. También incluye métodos de ablación de la médula ósea para su uso en tratamientos que requieran reacondicionamiento o trasplante de médula ósea.Compositions and methods for the treatment of leukemia, for example, acute myeloid leukemia (AML) and acute lymphoid B-cell leukemia (B-ALL). It also refers to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising it, and recombinant T cells comprising CAR-CD123. It also includes methods of administration of a genetically modified T cell expressing a CAR comprising a CD123 binding domain. It also includes bone marrow ablation methods for use in treatments that require reconditioning or bone marrow transplantation.

ARP140100533A 2013-02-20 2014-02-20 EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123 AR100010A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361767058P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
AR100010A1 true AR100010A1 (en) 2016-09-07

Family

ID=58699960

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100533A AR100010A1 (en) 2013-02-20 2014-02-20 EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123

Country Status (1)

Country Link
AR (1) AR100010A1 (en)

Similar Documents

Publication Publication Date Title
UY35340A (en) EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123
AU2023200884B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
IL279300A (en) Glp-1 receptor agonists and uses thereof
IL279224A (en) Glp-1 receptor agonists and uses thereof
CO2017001573A2 (en) Chimeric anti-cd123 antigen receptor
IL280718A (en) T cell receptor constructs and uses thereof
MX2017005051A (en) Heterophasic polypropylene with improved stiffness/impact balance.
SA518391159B1 (en) Affinity-Oligonucleotide Conjugates and Uses Thereof
CO2017000510A2 (en) Car constructs
CO2017000507A2 (en) Chimeric bcma antigen receptor
BR112019011450A2 (en) modified natural killer cells and their use
MX2017004539A (en) Heterophasic polypropylene with improved impact strength/stiffness balance, improved powder flowability, reduced emissions and low shrinkage.
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
MX2020001450A (en) Methods and compositions for reducing immunosupression by tumor cells.
MX2016013512A (en) Systems and methods for concurrent spectrum usage within actively used spectrum.
SG10201912494TA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
IL280318A (en) Resin composition suitable for printing and printing methods
SG11202007660UA (en) Cyclin a1 specific t cell receptors and uses thereof
AR112602A1 (en) ANTI-TrkB ANTIBODIES
IT201700037319A1 (en) NATURAL COMPOSITION FOR USE IN GYNECOLOGY
AR100010A1 (en) EFFECTIVE MARKING OF HUMAN LEUKEMIA USING CELLS DESIGNED WITH AN ANTIGEN CHEMERIC RECEIVER ANTI-CD123
PL3781632T3 (en) Antifreeze composition
GB201817450D0 (en) Battery composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure